0:00
Raloxifene launched
Dr. Reddy’s Laboratories Ltd (BSE: 500124, NSE: DRREDDY, NYSE: RDY) has launched Raloxifene hydrochloride tablets in 60 mg, a therapeutic equivalent generic version of Evista® (raloxifene hydrochloride) tablets in the United States.
It has been approved by the U.S. Food & Drug Administration.
The Evista® brand and generic had U.S. sales of approximately US$265 million MAT for the most recent twelve months ending in September 2016 according to IMS Health*.
Dr. Reddy’s Raloxifene tablets are available in 60 mg in bottle count sizes of 30, 100 and 1,000.
Evista® is a registered trademark of Eli Lilly and Company. fii-news.com
